Oramed Pharmaceuticals (ORMP) 10-K 14 Nov 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Aug. 31, 2014	Nov. 12, 2014	Feb. 28, 2014
Document and Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Aug-14	'	'
Entity Registrant Name	'ORAMED PHARMACEUTICALS INC.	'	'
Entity Central Index Key	'0001176309	'	'
Current Fiscal Year End Date	'--08-31	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2014	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$128,906,265
Entity Common Stock, Shares Outstanding	'	10,106,305	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Aug. 31, 2014	Aug. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS:	'	'
Cash and cash equivalents	$1,762	$2,272
Short term deposits (note 2)	18,481	5,247
Marketable securities (note 3)	1,047	956
Restricted cash (note 1l)	16	16
Prepaid expenses and other current assets	64	90
Related parties (note 12)	330	5
Grants receivable from the chief scientist	78	58
Total current assets	21,778	8,644
LONG TERM DEPOSITS AND INVESTMENT	3	5
AMOUNTS FUNDED IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT (note 6)	7	5
PROPERTY AND EQUIPMENT, NET (note 4)	14	6
Total assets	21,802	8,660
CURRENT LIABILITIES -	'	'
Accounts payable and accrued expenses	926	434
Related Parties (note 12c)	47	64
Total current liabilities	973	498
LONG TERM LIABILITIES:	'	'
Employee rights upon retirement (note 6)	9	8
Provision for uncertain tax position (note 11e)	27	23
Total long term liabilities	36	31
COMMITMENTS (note 7)	'	'
STOCKHOLDERS' EQUITY:	'	'
Common stock, $ 0.012 par value (30,000,000 and 16,666,667 authorized shares as of August 31, 2014 and 2013, respectively; 10,102,555 and 7,937,872 shares issued and outstanding as of August 31, 2014 and 2013, respectively)	121	95
Accumulated other comprehensive income	452	304
Additional paid-in capital	48,040	29,856
Accumulated loss	-27,820	-22,124
Total stockholders' equity	20,793	8,131
Total liabilities and stockholders' equity	$21,802	$8,660

CONSOLIDATED_BALANCE_SHEETS_PA

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) (USD $)	Aug. 31, 2014	Aug. 31, 2013
CONSOLIDATED BALANCE SHEETS [Abstract]	'	'
Common stock, par value per share	$0.01	$0.01
Common stock, shares authorized	30,000,000	16,666,667
Common stock, shares issued	10,102,555	7,937,872
Common stock, shares outstanding	10,102,555	7,937,872

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]	'	'	'
RESEARCH AND DEVELOPMENT EXPENSES, NET	$3,277	$2,272	$1,681
GENERAL AND ADMINISTRATIVE EXPENSES	2,629	2,032	1,203
OPERATING LOSS	5,906	4,304	2,884
FINANCIAL INCOME (note 10a)	-225	-180	-13
IMPAIRMENT OF AVAILABLE- FOR-SALE SECURITIES	'	'	184
FINANCIAL EXPENSES (note 10b)	11	313	199
LOSS BEFORE TAXES ON INCOME	5,692	4,437	3,254
INCOME TAX EXPENSES (BENEFIT) (note 11)	4	-205	90
NET LOSS FOR THE YEAR	5,696	4,232	3,344
SUBSEQUENT INCREASE IN THE FAIR VALUE OF AVAILABLE FOR SALE SECURITIES PREVIOUSLY WRITTEN DOWN AS IMPAIRED	-34	-131	'
RECLASSIFICATION ADJUSTMENT FOR GAINS INCLUDED IN NET LOSS	80	90	'
UNREALIZED GAIN ON AVAILABLE FOR SALE SECURITIES	-194	-263	'
TOTAL OTHER COMPREHENSIVE INCOME	-148	-304	'
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$5,548	$3,928	$3,344
BASIC AND DILUTED LOSS PER COMMON SHARE	$0.62	$0.59	$0.57
WEIGHTED AVERAGE NUMBER OF COMMON SHARES USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK	9,244,059	7,209,283	5,884,595

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]		Additional paid-in capital [Member]	Accumulated other comprehensive income [Member]	Accumulated loss [Member]
In Thousands, except Share data
BALANCE at Aug. 31, 2011	$3,723	$70		$18,201	'	($14,548)
BALANCE, shares at Aug. 31, 2011	'	5,844,000		'	'	'
SHARES AND WARRANTS ISSUED FOR CASH, NET (see note 8b and 8c)	2,995	10		2,985	'	'
SHARES AND WARRANTS ISSUED FOR CASH, NET (see note 8b and 8c), shares	'	802,000		'	'	'
SHARES AND WARRANTS TO BE ISSUED FOR CASH (see note 8b)	25	'		25	'	'
SHARES AND WARRANTS TO BE ISSUED FOR CASH (see note 8b), shares	'	'		'	'	'
SHARES ISSUED FOR SERVICES	108	'	[1]	108	'	'
SHARES ISSUED FOR SERVICES, shares	'	29,000		'	'	'
STOCK BASED COMPENSATION EXPENSE	271	'		271	'	'
NET LOSS	-3,344	'		'	'	-3,344
OTHER COMPREHENSIVE INCOME	'	'		'	'	'
BALANCE at Aug. 31, 2012	3,778	80		21,590	'	-17,892
BALANCE, shares at Aug. 31, 2012	'	6,675,000		'	'	'
SHARES AND WARRANTS ISSUED FOR CASH, NET (see note 8b and 8c)	1,422	4		1,418	'	'
SHARES AND WARRANTS ISSUED FOR CASH, NET (see note 8b and 8c), shares	'	349,000		'	'	'
SHARES ISSUED FOR CASH, NET (see note 8d and 8g)	4,239	8		4,231	'	'
SHARES ISSUED FOR CASH, NET (see note 8d and 8g), shares	'	658,000		'	'	'
SHARES ISSUED FOR MARKETABLE SECURITIES (see note 8b)	628	2		626	'	'
SHARES ISSUED FOR MARKETABLE SECURITIES (see note 8b), shares	'	199,000		'	'	'
SHARES ISSUED FOR SERVICES	245	'	[1]	244	'	'
SHARES ISSUED FOR SERVICES, shares	'	34,000		'	'	'
EXCHANGE OF WARRANTS (see note 5)	918	'		918	'	'
EXERCISE OF WARRANTS AND OPTIONS	110	'	[1]	110	'	'
EXERCISE OF WARRANTS AND OPTIONS, shares	'	23,000		'	'	'
STOCK BASED COMPENSATION EXPENSE	719	'		719	'	'
NET LOSS	-4,232	'		'	'	-4,232
OTHER COMPREHENSIVE INCOME	304	'		'	304	'
BALANCE at Aug. 31, 2013	8,131	95		29,856	304	-22,124
BALANCE, shares at Aug. 31, 2013	7,937,872	7,938,000		'	'	'
SHARES ISSUED FOR CASH, NET (see note 8d and 8g)	14,887	19		14,868	'	'
SHARES ISSUED FOR CASH, NET (see note 8d and 8g), shares	'	1,580,000		'	'	'
SHARES ISSUED (see notes 7f)	102	'	[1]	102	'	'
SHARES ISSUED (see notes 7f), shares	'	16,000		'	'	'
EXERCISE OF WARRANTS AND OPTIONS	1,753	7		1,746	'	'
EXERCISE OF WARRANTS AND OPTIONS, shares	'	569,000		'	'	'
STOCK BASED COMPENSATION EXPENSE	1,468	'		1,468	'	'
NET LOSS	-5,696	'		'	'	-5,696
OTHER COMPREHENSIVE INCOME	148	'		'	148	'
BALANCE at Aug. 31, 2014	$20,793	$121		$48,040	$452	($27,820)
BALANCE, shares at Aug. 31, 2014	10,102,555	10,103,000		'	'	'
[1]	Represents an amount of less than $1.

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014		Aug. 31, 2013		Aug. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'		'		'
Net loss	($5,696)		($4,232)		($3,344)
Adjustments required to reconcile net loss to net cash used in operating activities:	'		'		'
Depreciation and amortization	6		5		15
Exchange differences and interest on deposits	-29		19		62
Stock based compensation	1,468		719		271
Common stock issued for services	102		244		108
Gain on sale of investment	-80		-50		'
Impairment of available for sale securities	'		'		184
Exchange of warrants	'		297		'
Changes in fair value of warrant liabilities	'		-45		143
Changes in operating assets and liabilities:	'		'		'
Prepaid expenses and other current assets	-319		-3		-31
Accounts payable and accrued expenses	475		-146		203
Liability for employee rights upon retirement	1		1		-2
Provision for uncertain tax position	4		-205		90
Total net cash used in operating activities	-4,068		-3,396		-2,301
CASH FLOWS FROM INVESTING ACTIVITIES:	'		'		'
Purchase of property and equipment	-14		-6		-2
Purchase of short term deposits	-55,750		-5,847		-475
Proceeds from sale of short term deposits	42,539		1,054		1,800
Proceeds from sale of marketable securities	137		227		450
Funds in respect of employee rights upon retirement	-2		-2		-4
Other	2		5		'
Total net cash used in investing activities	-13,088		-4,569		1,769
CASH FLOWS FROM FINANCING ACTIVITIES:	'		'		'
Proceeds from issuance of common stock and warrants - net of issuance expenses	14,887	[1]	5,715	[1]	3,489	[1]
Proceeds from exercise of warrants and options	1,753		109		'
Total net cash provided by financing activities	16,640		5,824		3,489
EFFECT OF EXCHANGE RATE CHANGES ON CASH	6		-18		-39
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	-510		-2,159		2,918
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	2,272		4,431		1,513
CASH AND CASH EQUIVALENTS AT END OF PERIOD	1,762		2,272		4,431
Material non cash investing and financing activities:	'		'		'
Exchange of warrants	'		918		'
Shares issued for marketable securities	'		628		'
Shares and warrants to be issued for cash	'		'		$25
[1]	See notes 8a, 8b and 8d.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Aug. 31, 2014
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:
	a.              General
	1)            Incorporation and operations
	Oramed Pharmaceuticals Inc. (the “Company”) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd (“Hadasit”) to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes.
	On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.
	On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term “Group” refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the “Subsidiary”).
	2)            Development and liquidity risks
	The Group is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated any revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable.
	Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.
	Based on its current cash resources and commitments, and cash received in private and public offerings in the years ended August 31, 2014 and 2013, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond after the date that the financial statements are issued, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.
	3)            Reverse stock split
	On January 10, 2013, the Company's Board of Directors approved a reverse stock split at a ratio of one-for-twelve, effective January 22, 2013, which decreased the number of common shares issued and outstanding as of January 23, 2013, from approximately 86.5 million shares to approximately 7.2 million shares and the number of authorized common shares from 200 million shares to approximately 16.7 million shares. All share and per share data were retrospectively adjusted as a result of the split.
	b.             Accounting principles
	The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).
	c.            Use of estimates in the preparation of financial statements
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates.
	As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock based compensation.
	d.            Functional currency
	The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its Subsidiary is the dollar.
	Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.
	e.             Principles of consolidation
	The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.
	f.             Income taxes
	1. Deferred taxes
	Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.
	Regarding the Subsidiary, the recognition is prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities.
	Taxes that would apply in the event of disposal of investments in the Subsidiary have not been taken into account in computing deferred taxes, as it is the Company's intention to hold this investment, not to realize it.
	2. Uncertainty in income tax
	The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company's policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses.
	g.            Research and development, net
	Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company's clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred.
	Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.
	Grants received from the OCS and from Bio-Jerusalem are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grants are deducted from the related research and development expenses as the costs are incurred and are presented in R&D expenses, net. See also notes 7(j) and 7(k).
	h.            Cash equivalents
	The Company considers all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.
	i.             Loss per common share
	Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding. Outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options and warrants excluded from the calculation of diluted net loss was 1,924,491 for the year ended August 31, 2014 (2,343,972 and 1,892,180 for the years ended August 31, 2013 and 2012, respectively).
	j.             Stock based compensation
	Equity awards granted to employees are accounted for using the grant date fair value method. The fair value of share based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The expected service period is estimated using the simplified method due to insufficient specific historical information of employees' exercise behavior. The forfeitures are estimated based on historical experience and anticipated future conditions.
	The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.
	k.            Warrants issued as part of capital raisings that are classified as a liability
	Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) are classified as liabilities in the statement of financial position.
	The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. See note 5.
	l.              Fair value measurement:
	Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:
	Level 1:              Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
	Level 2:              Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
	Level 3:              Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	As of August 31, 2014 the assets or liabilities measured at fair value comprise of available for sale securities (level 1).
	In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.
	The Company has placed a restricted deposit with a certain bank in an amount of $16 as security for its credit card activity.
	Available-for-sale securities are reported at fair value, with unrealized gains and losses, net of related tax recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.
	The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company's ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses.
	m.           Concentration of credit risks
	Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short term deposit and marketable securities which are deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balances is remote.
	n.            Property and equipment
	Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the assets.
	Annual rates of depreciation are as follows:
		%
	Computers and peripheral equipment	33
	Office furniture and equipment	15-33
	Leasehold improvements are amortized over the term of the lease which is shorter than the estimated useful life of the improvements.
	o.            Newly issued and recently adopted accounting pronouncements:
1.    In August 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Currently, there is no guidance under U.S. GAAP about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern or to provide related footnote disclosures. The amendments in ASU 2014-15 provide that guidance. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. This new standard requires management to assess the entity's ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management's plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management's plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 will be effective prospectively for annual reporting periods ending after the first annual period ending after December 15, 2016 and interim periods therein. Early application of the standard is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued. The Company has elected to early adopt the provisions of ASU 2014-15 in fiscal year 2014.
2.              In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”). This update removes the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. The amendments in ASU 2014-10 will be effective retrospectively except for the clarification to Topic 275, which shall be applied prospectively for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued. The Company has elected to adopt the provisions of ASU 2014-10 in the third quarter of fiscal year 2014, and therefore removed the inception to date information and all reference to development. As a result, the adoption of ASU 2014-10 only impacted the consolidated financial statement presentation.
3.              In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). This update requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, ASU 2013-02 requires presentation, either on the face of the income statement or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by respective line items of net income, but only if the amounts reclassified are required to be reclassified in their entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about these amounts. The amendments in ASU 2013-02 will be effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. The Company adopted ASU 2013-02 in the first quarter of fiscal year 2014. The adoption of ASU 2013-02 did not have any material effect on the consolidated financial statement presentation.

SHORT_TERM_DEPOSITS

SHORT TERM DEPOSITS	12 Months Ended
	Aug. 31, 2014
SHORT TERM DEPOSITS [Abstract]	'
SHORT TERM DEPOSITS	'
	NOTE 2 - SHORT TERM DEPOSITS:
	Amounts that represent bank deposits that do not meet the cash equivalent criteria are the following:
			31-Aug
			2014			2013
		Annual		Amount		Annual			Amount
		interest				interest
		rate				rate
	Dollar deposits		0.12-0.6%	$	18,481		0.6-1.06	%	$	5,112
	NIS deposits				-		1.93%			135
				$	18,481				$	5,247

MARKETABLE_SECURITIES

MARKETABLE SECURITIES	12 Months Ended
	Aug. 31, 2014
MARKETABLE SECURITIES [Abstract]	'
MARKETABLE SECURITIES	'
	NOTE 3 - MARKETABLE SECURITIES:
	Available-for-sale securities are reported at fair value, with unrealized gains and losses, recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.
	As of August 31, 2014, marketable securities consisted wholly of equity securities of D.N.A Biomedical Solutions Ltd ("D.N.A"). D.N.A. ordinary shares are traded on the Tel Aviv Stock Exchange and have a quoted price. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.
	During the years ended August 31, 2014 and 2013, the Subsidiary sold in aggregate 2,625,989 and 5,250,000 of the D.N.A ordinary shares for a total of $138 and $170, respectively. In March 2013 the Company sold 1,750,000 of the D.N.A. ordinary shares for $56.
	As of August 31, 2014, the Group owns approximately 9.8% of D.N.A's outstanding ordinary shares.
	The cost of the securities as of August 31, 2014 and 2013 is $590 and $652.
	The cost of the securities sold and the amount reclassified out of accumulated other comprehensive income into financial income (amounting to $80 and $90 during the years ended August 31, 2014 and 2013, respectively), were determined by specific identification.
	As of August 31, 2014 and 2013, the available for sale securities are classified as Level 1.
	As of August 31, 2014, the carrying amount of cash and cash equivalents, short term deposits, accounts receivable, other current assets and accounts payables and accrued expenses approximates their fair values due to the short-term maturities of these instruments.
	The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

PROPERTY_AND_EQUIPMENT_NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Aug. 31, 2014
PROPERTY AND EQUIPMENT, NET [Abstract]	'
PROPERTY AND EQUIPMENT, NET	'
	NOTE 4 - PROPERTY AND EQUIPMENT, NET:
	a.              Composition of property and equipment, grouped by major classifications, is as follows:
		31-Aug
		2014		2013
	Cost:
	Leasehold improvements	$	78	$	76
	Office furniture and equipment		28		20
	Computers and peripheral equipment		38		34
			144		130
	Less - accumulated depreciation and amortization		130		124
		$	14	$	6
	b.              Depreciation expenses totaled $6, $5, and $15 in the years ended August 31, 2014 and 2013, and 2012, respectively.

WARRANTS

WARRANTS	12 Months Ended
	Aug. 31, 2014
WARRANTS [Abstract]	'
WARRANTS	'
	NOTE 5 - WARRANTS
	As part of the Company's private placements in 2011 and 2012, three warrants to purchase in aggregate 311,797 shares were granted to a Leading Investor, as defined in note 8a (collectively, the "Warrants"). The Warrants were granted for five years at an initial exercise price of $6.00 per share. The Warrants included a full ratchet anti-dilution protection from the second year anniversary date after issuing the warrant, subject to certain limitations. In the event the Company was to issue or sell any common stock for a consideration per share lower than the exercise price then in effect, or was to issue or sell any options, warrants or other rights for the purchase or acquisition of such shares at a consideration per share of less than the exercise price then in effect, the warrants were to be amended to (a) reduce the exercise price to an amount equal to the per share consideration payable to the company in such sale or issuance, and (b) the quantity of warrants were to be updated.
	As a result of a private placement in August 2012, and the agreement with D.N.A from October 2012, as described in note 8b, the warrant that was issued in 2011 was twice amended in such that its exercise price was reduced to $3.7656 per share and the number of shares issuable upon its exercise was increased to 290,459.
	On November 29, 2012, the Company and the Leading Investor entered into a letter agreement (the “Agreement”) in connection with the Warrants, pursuant to the which, the Company and the Leading Investor agreed to amend the Warrants to remove the anti-dilution protection in its entirety. In addition, as to the Warrants issued in August and November 2012,  the exercise price was reduced to $3.7656 per share. On that day, the Company also issued to the Leading Investor an additional warrant to purchase up to 137,311 shares of the Company over a period of four years at an exercise price of $7.20 per share. The fair value of the new warrant at the date of grant was $145, using the following assumptions: dividend yield of 0%, expected term of four years, expected volatility of 62.29% and risk-free interest rate of 0.57%.
	The fair value of the warrants was determined by using a Monte Carlo type model based on the risk neutral approach. The significant unobservable input used in the fair value measurement is the future expected issue dates. Significant delay in this input would result in a higher fair value measurement.
	In addition to the new warrants, the Company's President, Chief Executive Officer and director (the "CEO"), in his personal capacity as a shareholder of the Company, undertook and agreed that following the execution and delivery of the Agreement, in the event that an adjustment pursuant to the anti-dilution protection of any of the Warrants, as amended, would have been triggered and the number of shares of common stock of the Company that the Leading Investor would have been able to purchase under the Warrants would have increased by an aggregate number in excess of 137,311 shares, then the Leading Investor shall have the right to purchase from the CEO such number of shares of common stock of the Company owned by the CEO equal to such excess, up to a maximum of 112,690 shares of common stock of the Company (the “CEO Option”). The foregoing right shall survive until the expiration date of such Warrants. The fair value of the CEO Option on the date of grant was $168, based on the Monte Carlo type model and was recognized as an expense against the stockholders equity.
	Following the removal of the anti-dilution protection, the Warrants were no longer classified as liabilities. The Company recognized a financial expense in the amount of $297 during the three months ended November 30, 2012.
	The following table summarizes the activity for those financial liabilities where fair value measurements are estimated utilizing Level 3 inputs for the years ended August 31, 2013 and 2012. There were no Level 3 items for the year ended August 31, 2014.
		Year ended August 31,
		2013			2012
	Carrying value at the beginning of the period	$	637		$	-
	Additions		28			494
	Changes in fair value		(44	)		143
	Exchange of warrants		(621	)		-
	Carrying value at the end of the period	$	-		$	637
	See note 8g with respect to outstanding warrants.

EMPLOYEES_RIGHTS_UPON_RETIREME

EMPLOYEES RIGHTS UPON RETIREMENT	12 Months Ended
	Aug. 31, 2014
EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]	'
EMPLOYEE RIGHTS UPON RETIREMENT	'
	NOTE 6 - EMPLOYEES RIGHTS UPON RETIREMENT:
	The Subsidiary is required to make a severance payment upon dismissal of an employee, or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month's salary for each year employed) is recorded on the Subsidiary's balance sheets under “Liability for employee rights upon retirement.” The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.
	The liability is funded in part by the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Subsidiary's balance sheets under “Funds in respect of employee rights upon retirement.” These policies are the Subsidiary's assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In each of the years ended August 31, 2014 and 2013 the Subsidiary deposited $2, and in the year ended August 31, 2012 deposited $4 with insurance companies in connection with its severance payment obligations.
	In accordance with the current employment agreements with certain employees, the Subsidiary makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's rights upon retirement. The Subsidiary is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Subsidiary's balance sheets, as the amounts funded are not under the control and management of the Subsidiary and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the “Contribution Plans”).
	The amounts of severance pay expenses were $26,$23 and $6 for the years ended August 31, 2014, 2013 and 2012, respectively. $26, $13 and $7 in the years ended August 31, 2014, 2013 and 2012, respectively, were in respect of a Contribution Plan.
	The Subsidiary expects to contribute approximately $27 in the year ending August 31, 2015 to insurance companies in connection with its severance liabilities for its operations for that year.

COMMITMENTS

COMMITMENTS	12 Months Ended
	Aug. 31, 2014
COMMITMENTS [Abstract]	'
COMMITMENTS	'
	NOTE 7 - COMMITMENTS:
	a.   In March 2011, the Subsidiary sold shares of its investee company, Entera Bio Ltd (“Entera”) to D.N.A (see also note 3), retaining a 3% interest, which is accounted for as a cost method investment (amounting $1). In consideration for the shares sold to D.N.A, the Company received a promissory note issued by D.N.A in the principal amount of $450, with an annual interest rate of 0.45% that was fully paid in November 2011, and 8,404,667 ordinary shares of D.N.A.
	As part of this agreement, the Subsidiary entered into a patent transfer agreement according to which, the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera's net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of August 31, 2014, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary.
	b.     On September 11, 2011, the Subsidiary entered into an agreement with Hadasit, the Company's Medical and Chief Technology Officer (the "CTO") and Dr. Daniel Schurr (the “Hadasit Agreement”) to retain consulting and clinical trial services. According to the Hadasit Agreement, Hadasit will be entitled to a consideration of $200 to be paid by the Company in accordance with the actual progress of the studies, $95 of which were recognized through August 31, 2014. See also note 1a(1).
	c.     On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the “Consultant”) for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera  on March 31, 2011 and an option to purchase up to 20,834 shares of the Company at an exercise price of $6.00 per share. The option vests in five annual installments commencing February 16, 2012 and expires on February 16, 2021. The initial fair value of the option on the date of grant was $62, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 78.65%; risk-free interest rates of 3.62%; and the remaining expected term of 10 years. The fair value of the option as of August 31, 2014 was $111, using the following assumptions: dividend yield of 0% and expected term of 6.46 years; expected volatility of 81.31%; and risk-free interest rate of 2.05%. The fair value of the unvested options is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.
	d.     On March 18, 2012, the Subsidiary entered into a lease agreement for its facilities in Israel. The lease agreement was for a period of 57 months commencing January 1, 2012.
	On April 28, 2013, the Subsidiary entered into a new lease agreement for its office facilities in Israel, which replaced the lease agreement from 2012. The new lease agreement is for a period of 36 months commencing November 4, 2013. The annual lease payment will be NIS 89 from 2014 through 2016, and will be linked to the increase in the Israeli consumer price index (“CPI”) (as of August 31, 2014, the future annual lease payments under the new agreement will be $25, based on the exchange rate as of August 31, 2014).
	The lease expenses for the years ended August 31, 2014, 2013 and 2012 were $27, $13 and $9, respectively.
	The future lease payments under the lease agreement are $25 in each of the years ending August 31, 2015 and 2016, and $2 for the year ending August 31, 2017.
	As security for its obligation under this lease agreement the Company provided a bank guarantee in an amount equal to three monthly lease payments.
	e.    The Subsidiary has entered into operating lease agreements for vehicles used by its employees for a period of 3 years.
	The lease expenses for the years ended August 31, 2014, 2013 and 2012 were $28, $30 and $30, respectively.
	The future lease payments under the lease agreement are $18 and $14 for the years ending August 31, 2015 and 2016, respectively.
	As security for its obligation under the lease agreements the Subsidiary deposited $2, which are classified as long term deposits.
	f.    On August 15, 2011, the Company entered into a consulting agreement with a third party advisor for a period of nine months, pursuant to which such advisor provided investor relations services and received a monthly cash fee and shares of the Company's common stock that were issued in three equal installments as follows: on each of December 12, 2011, March 14, 2012 and May 15, 2012, the Company issued 6,917 shares at a fair value of $25, $27 and $25, respectively
	On April 15, 2013, the Company entered into an additional consulting agreement with the same third party advisor for a period of twelve months, pursuant to which such advisor provided investor relations services and received a monthly cash fee and 15,000 shares of the Company's common stock. On July 11 and November 4, 2013 the Company issued to such advisor 5,000 and 10,000 shares, respectively. The fair value of the shares at these dates was $35 and $64, respectively.
	On May 13, 2014, the Company entered into an additional consulting agreement with the same third party advisor for a period of an additional twelve months, pursuant to which such advisor will provide investor relations services and will be entitled to receive a monthly cash fee and 15,000 shares of the Company's common stock that will be issued in four equal installments, on each of August 1, 2014, November 1, 2014, February 1, 2015 and May 1, 2015. As of August 31, 2014 the Company issued to such advisor 3,750 shares. The fair value of the shares at that date was $38.
	g.     On April 29, 2013, the Subsidiary entered into a Clinical Research Organization Service Agreement with a third party, to retain it as a Clinical Research Organization (“CRO”), for its Phase IIa clinical trial for an oral insulin capsule for type 2 diabetes patients. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $333 that will be paid during the term of the engagement and based on achievement of certain milestones, all of which were recognized through August 31, 2014.
	On February 6, 2014, the Subsidiary entered into a second agreement with the same CRO, for its Phase IIa clinical trial for an oral insulin capsule for type 1 diabetes patients, which was completed in October 2014. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $280 that will be paid during the term of the engagement and based on achievement of certain milestones, $182 of which were recognized through August 31, 2014.
	On July 22, 2014, the Subsidiary entered into a third agreement with the same CRO, for its Phase 2b clinical trial for an oral insulin capsule for type 2 diabetes patients, which is expected to be begin in the first quarter of calendar year 2015. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $3,290 that will be paid during the term of the engagement and based on achievement of certain milestones, $64 of which were recognized through August 31, 2014.
	h.     On July 23, 2013, the Subsidiary entered into a Master Service Agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $102, all of which was recognized through August 31, 2014.
	On March 3, 2014, the Subsidiary entered into an additional agreement with the same vendor, for the process development and production of one of its oral capsule ingredients in a different technology in the amount of $311, $40 of which was recognized through August 31, 2014, and bonus payments of up to $600 that will be paid upon achieving certain milestones, as described in the agreement, none of which was recognized through August 31, 2014.
	On May 15, 2014, the Subsidiary entered into an additional agreement with the same vendor, for the process development and production of the same capsule ingredients in the amount of $217,  $103 of which was recognized through August 31, 2014.
	i.     On May 26, 2014, the Subsidiary entered into a supply agreement with a vendor, according to which, the vendor will manufacture insulin capsules for total consideration of $214, $47 of which were recognized through August 31, 2014.
	j.      Grants from Bio-Jerusalem
	The Subsidiary is committed to pay royalties to the Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $65. As of August 31, 2014, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.
	During the years ended August 31, 2014 and 2012, the Company received no grants from the Bio-Jerusalem fund. For the year ended August 31, 2013, the research and development expenses are presented net of Bio-Jerusalem grants, in the total amount of $12.
	k.      Grants from the Chief Scientist Office (“OCS”)
	Under the terms of the Company's funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of annual interest at a rate based on LIBOR.
	At the time the grants were received, successful development of the related projects was not assured. In case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties.
	On August 31, 2014, the Subsidiary had not yet realized any revenues from the said project and did not incur any royalty liability. The total amount that was actually received through August 31, 2014 was $2,066.
	For the years ended August 31, 2014, 2013 and 2012, the research and development expenses are presented net of OCS Grants, in the total amount of $428, $297 and $373, respectively.

STOCK_HOLDERS_EQUITY

STOCK HOLDERS' EQUITY	12 Months Ended
	Aug. 31, 2014
STOCK HOLDERS' EQUITY [Abstract]	'
STOCK HOLDERS' EQUITY	'
	NOTE 8 - STOCKHOLDERS' EQUITY:
	In February 2013 the Company's common stock began trading on the Nasdaq Capital Market under the symbol ORMP. Before then it was traded on the Over-The-Counter Bulletin Board.
	The following are the significant capital stock transactions that took place during the years ended August 31, 2014, 2013 and 2012:
		a.		In August 2012, the Company entered into Securities Purchase Agreements with a number of investors for the sale of 801,942 units at a purchase price of $4.44 per unit for total consideration of $3,560. Each unit consisted of one share of the Company and one common stock purchase warrant. Each warrant entitles the holder to purchase half a share exercisable for five years at an exercise price of $6.00 per share. The investors were granted customary registration rights with respect to resales of shares, including the shares underlying the warrants. In addition, one of the investors who was previously defined as a leading investor (the "Leading Investor"), who purchased 225,226 of the units, was granted the right to maintain its percentage of the shares of the Company's common stock outstanding by purchasing more shares whenever the Company proposes to issue certain additional shares to other investors.  Such right only exists so long as such investor holds at least 5% of the Company's outstanding common stock.  In addition, such investor's warrants contained anti-dilution protection (the "full ratchet anti-dilution protection") and cashless exercise provisions not contained in the other investors' warrants.  The other terms of the Leading Investor's Securities Purchase Agreement were substantially the same as those granted to him in 2011 for his first investment. As to the amendment to the 2011 Warrants, see note 5.
	In addition, in August 2012, the Company entered into a Securities Purchase Agreement with an investor for the sale of 5,652 units at same terms as describe above. As the payment from said investor was received during September 2012, following which, the Company issued him 5,652 shares of its common stock and a warrant to purchase 2,826 shares of its common stock, the proceeds from that investment, of $25 were presented as shares and warrants to be issued for cash.
	The Company paid cash consideration of $71 as finders' fees in connection with the Securities Purchase Agreements.
		b.		Between September and November 2012, the Company entered into Securities Purchase Agreements with a number of investors for the sale of 329,872 units at a purchase price of $4.44 per unit for total consideration of $1,464. Each unit consisted of one share of the Company's common stock and one common stock purchase warrant. Each warrant entitles the holder to purchase 0.50 a share of common stock exercisable for five years at an exercise price of $6.00 per share. The investors were granted customary registration rights with respect to resales of shares, including the shares underlying the warrants. In addition, the Leading Investor, who purchased 33,784 of the units, was granted the right to maintain its percentage of the shares of the Company's common stock outstanding by purchasing more shares whenever the Company proposes to issue certain additional shares to other investors. Such right only exists so long as such investor holds at least 5% of the Company's outstanding common stock. In addition, such investor's warrants contained full ratchet anti-dilution protection and cashless exercise provisions not contained in the other investors' warrants. The other terms of the Leading Investor's Securities Purchase Agreement were substantially the same as those granted to him in 2011 for his first investment. As to the amendment to certain Warrants, and the removal of the full ratchet anti-dilution protection see note 5.
	As a finder's fee, in connection with the securities purchase agreements, the Company paid cash consideration of $13, as well as issued 1,127 shares of the Company and 564 common stock purchase warrant to another individual. The Company also issued 12,745 shares of the Company and 6,373 common stock purchase warrants to a director as a finder's fee with respect to the Securities Purchase Agreements described above and to the Securities Purchase Agreements to which the Company had entered into in August 2012.
		c.	On October 30, 2012, the Company entered into a Securities Purchase Agreement with D.N.A, according to which, the Company issued on that day to D.N.A 199,172 shares of its common stock, in consideration for the option to purchase up to 21,637,611 ordinary shares of D.N.A, valued at approximately $629 at the day of the transaction. The Company exercised the option in February 2013. See also note 3.
		d.	On July 10, 2013, the Company entered into a Placement Agency Agreement with Aegis Capital Corp. as representative of the several placement agents (the “Placement Agents”), pursuant to which the Placement Agents agreed to use their reasonable best efforts to arrange for the sale of up to 658,144 shares of the Company's common stock. In connection therewith, on July 10, 2013, the Company also entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell an aggregate of 658,144 shares at a price of $7.00 per share, to various investors in a registered direct offering (the “Offering”). The Company received all funds and issued all shares in connection with the Offering as of July 17, 2013. The net proceeds to the Company from the offering are approximately $4,239, after deducting Placement Agents' commissions of $255 and other offering expenses of the Company.
		e.	On December 24, 2013, the Company entered into a Placement Agency Agreement with the Placement Agent, pursuant to which the Placement Agent agreed to use its reasonable best efforts to arrange for the sale of up to 1,580,000 shares of the Company's common stock.  In connection therewith, on December 24, 2013, the Company entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell an aggregate of 1,580,000 shares of common stock, at a price of $10.00 per share, to two institutional investors in a registered direct offering (the "Offering"). The net proceeds to the Company from the Offering were approximately $14,887, after deducting Placement Agent's commissions of $816 and other offering expenses of the Company.
		f.	On July 23, 2014, the Company's shareholders approved an amendment to the Company's Certificate of Incorporation to increase the Company's authorized common stock from 16,666,667 shares to 30,000,000 shares.
		g.	As of August 31, 2014, the Company had outstanding warrants exercisable for 953,369 shares of common stock at exercise prices ranging from $3.7656 to $7.20 expiring at various dates between November 11, 2015 and February 2, 2018.
	The following table presents the warrant activity for the years ended August 31, 2014, 2013 and 2012:
			2014					2013					2012
			Warrants			Weighted-Average Exercise Price		Warrants			Weighted-Average Exercise Price*				Weighted-Average Exercise Price*
													Warrants
	Warrants outstanding as of September 1			1,215,034		$	5.33		883,191		$	5.56		352,883	$	6
	Issued			-			-		353,285		$	4.79		530,308	$	5.28
	Exercised			(261,665	)	$	6		(21,442	)	$	6		-		-
	Warrants outstanding as of August 31			953,369		$	5.15		1,215,034		$	5.33		883,191	$	5.56
	Warrants exercisable as of August 31			952,258		$	5		1,213,478		$	5.33		852,024	$	5.55
	* See note 5 with regards to the amendment of price of certain warrants during the years ended August 31, 2012 and 2013.

STOCK_BASED_COMPENSATION

STOCK BASED COMPENSATION	12 Months Ended
	Aug. 31, 2014
STOCK BASED COMPENSATION [Abstract]	'
STOCK BASED COMPENSATION	'
	NOTE 9 - STOCK BASED COMPENSATION:
	As of August 31, 2014, the Company has one stock option plan, the Amended and Restated 2008 Stock Incentive Plan, under which, the Company had reserved a pool of 1,400,000 shares of the Company's common stock which may be issued at the discretion of the Company's Board of Directors from time to time. Under this Plan, each option is exercisable into one share of common stock of the Company.
	The options may be exercised after vesting and in accordance with vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the options is 10 years.
	The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods. The expected term is the length of time until the expected dates of exercising the options, and is estimated using the simplified method due to insufficient specific historical information of employees' exercise behavior.
	The following are the significant stock options transactions with executive and board members made during the years ended August 31, 2014, 2013 and 2012:
	a.    On August 8, 2012, options to purchase an aggregate of 144,000 shares of the Company were granted to the CEO and to the CTO, both related parties, at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant), the options vested with respect to 42,000 shares of common stock immediately on the date of grant and the remaining shares of common stock will vest in seventeen equal monthly installments of 6,000 each. These options expire on August 7, 2022.  The fair value of these options on the date of grant was $374, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 0.83%; and expected term of 5.5 years.
	b.    On August 8, 2012, options to purchase an aggregate of 43,334 shares of the Company were granted to three Board of Directors members at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant). The options vest in two equal annual installments, commencing January 1, 2013, and expire on August 7, 2022. The fair value of these options on the date of grant was $115, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 1.0375%; and expected term of 5.75 years.
	c.    On August 8, 2012, the Company's Board of Directors approved an extension of the term of the warrants to purchase 280,114 shares of the Company held by the CTO by approximately two years from such approval, expiring on August 6, 2014. The incremental fair value of the warrant extension was negligible.
	d.    On December 20, 2012, options to purchase 20,000 shares of the Company were granted to a director at an exercise price of $6.00 per share (higher than the traded market price on the date of grant). The options vested in two equal annual installments, commencing January 1, 2013, and expire on December 19, 2022. The fair value of these options on the date of grant was $41, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 64.35%; risk-free interest rates of 1.01%; and expected term of 5.75 years.
	e.    On April 9, 2014, options to purchase an aggregate of 94,268 shares of the Company were granted to the CEO and to the CTO, both related parties, at an exercise price of $12.45 per share (equivalent to the traded market price on the date of grant).  The options vested with respect to 31,420 shares of common stock on April 30, 2014, and the remaining shares of common stock vest in eight equal monthly installments of 7,586 each. These options expire on April 9, 2024.  The fair value of these options on the date of grant was $781, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 82.06%; risk-free interest rates of 1.65%; and expected term of 5.21 years.
	f.    On April 9, 2014, options to purchase an aggregate of 52,376 shares of the Company were granted to four Board of Directors members at an exercise price of $12.45 per share (equivalent to the traded market price on the date of grant). The options vest in two equal installments, on July 1, 2014 and January 1, 2015, and expire on April 9, 2024. The fair value of these options on the date of grant was $435, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 82.06%; risk-free interest rates of 1.65%; and expected term of 5.25 years.
	The fair value of each option grant is estimated on the date of grant using the Black Scholes option-pricing model with the following assumptions:
		For options granted in
		the year ended August
		31
		2014			2013			2012
	Expected option life (years)	5.21-5.25			5.75-6			5.5-5.75
	Expected stock price volatility (%)	82.06			64.35-75.46			76.03
	Risk free interest rate (%)	1.65			0.92-1.01			0.83-1.0375
	Expected dividend yield (%)	0.0			0			0
	A summary of the status of the stock options granted to employees and directors as of August 31, 2014, 2013 and 2012, and changes during the years ended on those dates, is presented below:
		Year ended August 31,
		2014						2013						2012
		Number			Weighted			Number			Weighted			Number			Weighted
		of			average			of			average			of			average
		options			exercise			options			exercise			options			exercise
					price						price						price
					$						$						$
	Options outstanding at beginning of year		1,049,249			4.13			932,116			3.72			834,116			3.84
	Changes during the year:
	Granted - at market price		149,200			12.45			100,800			7.88			244,334			4.08
	Granted - above market price		-			-			24,667			6			-			-
	Expired		-			-			-			-			(141,667	)		5.4
	Forfeited		-			-			-			-			(4,667	)		5.64
	Exercised		(289,548	)		0.18			(8,334	)		5.04			-			-
	Options outstanding at end of year		908,901			6.75			1,049,249			4.13			932,116			3.72
	Options exercisable at end of year		786,328						870,883						717,088
	Weighted average fair value of options granted during the year	$	8.31					$	4.55					$	2.65
	Costs incurred in respect of stock based compensation for employees and directors, for the years ended August 31, 2014, 2013 and 2012 were $1,422, $563 and $201, respectively.
	The total intrinsic value of employees options exercised during the years ended August 31, 2014 and 2013 was $2,847 and $18, respectively. None of the options were exercised by employees during the year ended August 31, 2012
	The following table presents summary information concerning the options granted to employees and directors outstanding as of August 31, 2014:
	Range of	Number			Weighted			Weighted			Aggregate
	exercise	outstanding			Average			average			intrinsic value
	prices				Remaining			exercise
					Contractual			price
					Life
	$				Years				$
	4.08 to 6.00		514,901			6.7			4.95			2,672
	6.48 to 7.88		244,800			5.72			7.06			755
	12.45		149,200			9.61			12.45			-
			908,901			6.91			6.75			3,427
	The following table presents summary information concerning the options granted to employees and directors exercisable as of August 31, 2014:
	Range of	Number			Weighted			Weighted			Aggregate
	exercise	exercisable			Average			average			intrinsic value
	prices				Remaining			exercise
					Contractual			price
					Life
	$				Years				$
	4.08 to 6.00		505,818			6.67			4.97			2,617
	6.48 to 7.88		190,200			4.88			6.82			631
	12.45		90,310			9.61			12.45			-
			786,328			6.58			6.27			3,248
	As of August 31, 2014 there were $292 of unrecognized compensation costs related to non-vested options previously granted to employees and directors, to be recorded over the next 20 months.
A summary of the status of the stock options granted to non-employees outstanding as of August 31, 2014, 2013 and 2012, and changes during the years ended on this date, is presented below:
	Year ended August 31
	2014						2013						2012
	Number			Weighted			Number			Weighted			Number			Weighted
	of			average			of			average			of			average
	options			exercise			options			exercise			options			exercise
				price						price						price
				$						$						$
Options outstanding at beginning of year		79,689			7.21			79,689			7.21			79,689			7.21
Changes during the year:
Exercised		(17,468	)		7.49			-						-			-
Options outstanding at end of year		62,221			7.13			79,689			7.21			79,689			7.21
Options exercisable at end of year		53,888						47,469						54,683
The Company recorded stock based compensation of $46, $156 and $117 during the years ended August 31, 2014, 2013 and 2012, respectively, related to non-employees awards.
The total intrinsic value of non-employees options exercised during the year ended August 31, 2014 was $187. None of the options were exercised by non-employees during the years ended August 31, 2013 and 2012.
The following table presents summary information concerning the options granted to non-employees outstanding as of August 31, 2014:
Range of		Number			Weighted			Weighted			Aggregate
exercise		outstanding			Average			Average			intrinsic value
prices					Remaining			Exercise
					Contractual			Price
					Life
$					Years				$
4.08 to 6.00			37,219			3.94			5.79			162
9.12			25,002			2.99			9.12			25
			62,221			3.56			7.13			187
The following table presents summary information concerning the options granted to non-employee exercisable as of August 31, 2014:
Range of	Number			Weighted			Weighted			Aggregate
exercise	exercisable			Average			average			intrinsic value
prices				Remaining			exercise
				Contractual			price
				Life
$				Years			$
4.08 to 6.00		28,886			3.21			5.73			128
9.12		25,002			2.99			9.12			25
		53,888			3.11			7.3			153
As of August 31, 2014 there were $49 of unrecognized compensation costs related to non-vested non-employee options, to be recorded over the next 18 months.

FINANCIAL_INCOME_AND_EXPENSES

FINANCIAL INCOME AND EXPENSES	12 Months Ended
	Aug. 31, 2014
FINANCIAL INCOME AND EXPENSES [Abstract]	'
FINANCIAL INCOME AND EXPENSES	'
	NOTE 10 - FINANCIAL INCOME AND EXPENSES
	a.              Financial income
		Year ended August 31
			2014		2013		2012
	Gain on sale of marketable securities (note 3)		$	80	$	90	$	-
	Changes in fair value of warrants			-		44		-
	Income from interest on deposits			138		19		13
	Exchange rate differences			7		-		-
	Other			-		27		-
			$	225	$	180	$	13
	b.              Financial expenses
			Year ended August 31
			2014		2013		2012
	Exchange of warrants		$	-	$	297	$	-
	Changes in fair value of warrants			-		-		143
	Exchange rate differences			-		3		35
	Bank commissions			11		13		15
	Other			-		-		6
			$	11	$	313	$	199

TAXES_ON_INCOME

TAXES ON INCOME	12 Months Ended
	Aug. 31, 2014
TAXES ON INCOME [Abstract]	'
TAXES ON INCOME	'
	NOTE 11 - TAXES ON INCOME:
	Taxes on income included in the consolidated statements of operations represent current taxes due to taxable income of the Company and its Subsidiary.
	a.    Corporate taxation in the U.S.
	The applicable corporate tax rate for the Company is 35%.
	As of August 31, 2014, the Company has an accumulated tax loss carryforward of approximately $6,626 (as of August 31, 2013, approximately $5,605). Under U.S. tax laws, subject to certain limitations, carryforward tax losses expire 20 years after the year in which incurred. In the case of the Company, subject to potential limitations in accordance with the relevant law, the net loss carryforward will expire in the years 2025 through 2032.
	b.    Corporate taxation in Israel:
	The Subsidiary is taxed in accordance with Israeli tax laws. The corporate tax rate applicable to 2013 and 2014 is 25% and 26.5%, respectively.
	As of August 31, 2014, the Subsidiary has an accumulated tax loss carryforward of approximately $9,713 (as of August 31, 2013, approximately $7,664).
	Deferred income taxes:
			31-Aug
			2014			2013			2012
	In respect of:
	Net operating loss carryforward			4,890			3,993			3,190
	Research and development expenses			688			339			18
	Less - valuation allowance			(5,578	)		(4,332	)		(3,208	)
	Net deferred tax assets			-			-			-
	Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a full valuation allowance.
	c.    Loss before taxes on income and income taxes included in the income statements of operations:
				Year ended
				31-Aug
				2014			2013			2012
	Loss before taxes on income:
	U.S.				893			1,186			599
	Outside U.S.				4,799			3,251			2,655
				$	5,692		$	4,437		$	3,254
	Income tax expenses (benefit):
	Current:
	U.S.				-			(13	)		(8	)
	Outside U.S.				4			(192	)		98
				$	4		$	(205	)	$	90
	d.    Reconciliation of the statutory tax benefit to effective tax expense
	Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates applicable to companies in the United States, and the actual tax expense:
				Year ended
				31-Aug
				2014				2013					2012
	Loss before income taxes as reported in the consolidated statement of comprehensive income (loss)			$	(5,692	)		$		(4,437	)		$	(3,254		)
	Statutory tax benefit				(1,992	)				(1,552	)				(1,139	)
	Increase (decrease) in income taxes resulting from:
	Change in the balance of the valuation allowance for deferred tax				1,104					902					517
	Disallowable deductions				480					374					120
	Increase in taxes resulting from different tax rates applicable to the Subsidiary				408					276					502
	Uncertain tax position				4					(205	)				90
	Taxes on income for the reported year			$	4			$		(205	)		$		90
	e.    Uncertainty in Income Taxes
	Accounting Standards Codification No.740 “Income Taxes” requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The Company recognizes interest and penalties related to its tax contingencies as income tax expense. For the three years ended August 31, 2014, the Company did not record any amount for penalties related to tax contingencies.
	The following table summarizes the activity of the Company unrecognized tax benefits:
				Year ended August 31
				2014					2013					2012
	Balance at Beginning of Year			$		23			$		228			$		138
	Increase (decrease) in uncertain tax positions for the current year					4					(205	)				90
	Balance at End of Year			$		27			$		23			$		228
	The increase in uncertain tax positions for the year ended August 31, 2014, is a result of additional accrual for uncertain tax position.
	The Company does not expect unrecognized tax expenses to change significantly over the next 12 months.
	The Company is subject to U.S. Federal income tax examinations for the tax years of 2009 through 2014.
	The Subsidiary is subject to Israeli income tax examinations for the tax years of 2010 through 2014.
	f.    Valuation Allowance Rollforward
		Year ended
		31-Aug
			Balance at beginning of period				Additions				Balance at end of period
	Allowance in respect of carryforward tax losses:
	Year ended August 31, 2014		$	4,332			$	1,246			$	5,578
	Year ended August 31, 2013		$	3,208			$	1,124			$	4,332
	Year ended August 31, 2012		$	1,813			$	1,395			$	3,208

RELATED_PARTIES_TRANSACTIONS

RELATED PARTIES - TRANSACTIONS	12 Months Ended
	Aug. 31, 2014
RELATED PARTIES - TRANSACTIONS [Abstract]	'
RELATED PARTIES - TRANSACTIONS	'
	NOTE 12 - RELATED PARTIES - TRANSACTIONS:
	a.    During each of the fiscal years of 2014, 2013 and 2012 the Company paid to directors $40, $39 and $30, respectively, as directors fee.
	b.    On July 1, 2008, the Subsidiary entered into a consulting agreement with KNRY Ltd. (“KNRY”), an Israeli company owned by the CEO, whereby the CEO, through KNRY, will provide services as President and Chief Executive Officer of both the Company and the Subsidiary (the “CEO's Consulting Agreement”). Additionally, on July 1, 2008, the Subsidiary entered into a consulting agreement with KNRY whereby the CTO, through KNRY, will provide services as Chief Medical and Technology Officer of both the Company and the Subsidiary (the “CTO's Consulting Agreement” and together with the CEOs Consulting Agreement, the “Consulting Agreements”). The Consulting Agreements are both terminable by either party upon 60 days prior written notice. The Consulting Agreements provide that KNRY (i) will be paid, under each of the Consulting Agreements, a gross amount of NIS 50,400 per month ($14) and (ii) will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements.
	On July 17, 2013, the Subsidiary entered into amendments to the Consulting Agreements with KNRY, according to which, the CEO's annual payment was set at $250 that will be calculated at an exchange rate of 3.6 NIS per U.S. dollar (actual payment of $257), and in addition to such payment he will be granted the use of a company car and a one time cash bonus of $60, and the CTO's annual payment was set at $200 that will be calculated at an exchange rate of 3.6 NIS per U.S. dollar (actual payment of $206), and in addition to such payment she was granted the use of a company car and a one time cash bonus of $20, both effective July 1, 2013.
	On February 24, 2014, the compensation committee of the Company's board of directors approved payment of cash bonuses to the CEO and the CTO in the amounts of $120 and $65, respectively.
	On March 18, 2014, the compensation committee of the Company's board of directors approved a temporary increase of nearly $7 per month for a specific period in which the CEO stayed in the United States. This payment replaced per diem payments for that business travel.
	c.    Balances with related parties:
			31-Aug
			2014			2013
	Receivable		$	330		$	5
	Accounts payable and accrued expenses - KNRY		$	47		$	64
	The receivable is the withholding tax from options exercised on August 1, 2014 which was received by the Company on September 12, 2014.
	d.     Expenses to related parties:
		31-Aug
		2014			2013			2012
	KNRY	$		671	$		448	$	318

SUBSEQUENT_EVENT

SUBSEQUENT EVENT	12 Months Ended
	Aug. 31, 2014
SUBSEQUENT EVENTS [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 13 - SUBSEQUENT EVENT
	In November 2014, the Company entered into a Securities Purchase Agreement with an investor for the sale of 696,378 share of the Company's common stock, at a price of $7.18 per share, which is equal to the closing price of the Company's common stock on the Nasdaq Capital Market on October 31, 2014. The closing date is expected to be on or before November 28, 2014. In connection with the offering, the Company will pay a finder's fee of up to $150.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policy)	12 Months Ended
	Aug. 31, 2014
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
General	'
	a.              General
	1)            Incorporation and operations
	Oramed Pharmaceuticals Inc. (the “Company”) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd (“Hadasit”) to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes.
	On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.
	On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term “Group” refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the “Subsidiary”).
	2)            Development and liquidity risks
	The Group is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated any revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable.
	Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.
	Based on its current cash resources and commitments, and cash received in private and public offerings in the years ended August 31, 2014 and 2013, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond after the date that the financial statements are issued, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.
	3)            Reverse stock split
	On January 10, 2013, the Company's Board of Directors approved a reverse stock split at a ratio of one-for-twelve, effective January 22, 2013, which decreased the number of common shares issued and outstanding as of January 23, 2013, from approximately 86.5 million shares to approximately 7.2 million shares and the number of authorized common shares from 200 million shares to approximately 16.7 million shares. All share and per share data were retrospectively adjusted as a result of the split.
Accounting principles	'
	b.             Accounting principles
	The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).
Use of estimates in the preparation of financial statements	'
	c.            Use of estimates in the preparation of financial statements
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates.
	As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock based compensation.
Functional currency	'
	d.            Functional currency
	The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its Subsidiary is the dollar.
	Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.
Principles of consolidation	'
	e.             Principles of consolidation
	The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.
Income taxes	'
	f.             Income taxes
	1. Deferred taxes
	Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.
	Regarding the Subsidiary, the recognition is prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities.
	Taxes that would apply in the event of disposal of investments in the Subsidiary have not been taken into account in computing deferred taxes, as it is the Company's intention to hold this investment, not to realize it.
	2. Uncertainty in income tax
	The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company's policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses.
Research and development	'
	g.            Research and development, net
	Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company's clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred.
	Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.
	Grants received from the OCS and from Bio-Jerusalem are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grants are deducted from the related research and development expenses as the costs are incurred and are presented in R&D expenses, net. See also notes 7(j) and 7(k).
Cash equivalents	'
	h.            Cash equivalents
	The Company considers all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.
Loss per common share	'
	i.             Loss per common share
	Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding. Outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options and warrants excluded from the calculation of diluted net loss was 1,924,491 for the year ended August 31, 2014 (2,343,972 and 1,892,180 for the years ended August 31, 2013 and 2012, respectively).
Stock based compensation	'
	j.             Stock based compensation
	Equity awards granted to employees are accounted for using the grant date fair value method. The fair value of share based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The expected service period is estimated using the simplified method due to insufficient specific historical information of employees' exercise behavior. The forfeitures are estimated based on historical experience and anticipated future conditions.
	The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.
Warrants issued as part of capital raisings that are classified as a liability	'
	k.            Warrants issued as part of capital raisings that are classified as a liability
	Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) are classified as liabilities in the statement of financial position.
	The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. See note 5.
Fair value measurement	'
	l.              Fair value measurement:
	Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:
	Level 1:              Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
	Level 2:              Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
	Level 3:              Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	As of August 31, 2014 the assets or liabilities measured at fair value comprise of available for sale securities (level 1).
	In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.
	The Company has placed a restricted deposit with a certain bank in an amount of $16 as security for its credit card activity.
	Available-for-sale securities are reported at fair value, with unrealized gains and losses, net of related tax recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.
	The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company's ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses.
Concentration of credit risks	'
	m.           Concentration of credit risks
	Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short term deposit and marketable securities which are deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balances is remote.
Property and equipment	'
	n.            Property and equipment
	Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the assets.
	Annual rates of depreciation are as follows:
		%
	Computers and peripheral equipment	33
	Office furniture and equipment	15-33
	Leasehold improvements are amortized over the term of the lease which is shorter than the estimated useful life of the improvements.
Newly issued and recently adopted Accounting Pronouncements	'
	o.            Newly issued and recently adopted accounting pronouncements:
	1.    In August 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Currently, there is no guidance under U.S. GAAP about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern or to provide related footnote disclosures. The amendments in ASU 2014-15 provide that guidance. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. This new standard requires management to assess the entity's ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management's plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management's plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 will be effective prospectively for annual reporting periods ending after the first annual period ending after December 15, 2016 and interim periods therein. Early application of the standard is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued. The Company has elected to early adopt the provisions of ASU 2014-15 in fiscal year 2014.
	2.              In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”). This update removes the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. The amendments in ASU 2014-10 will be effective retrospectively except for the clarification to Topic 275, which shall be applied prospectively for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued. The Company has elected to adopt the provisions of ASU 2014-10 in the third quarter of fiscal year 2014, and therefore removed the inception to date information and all reference to development. As a result, the adoption of ASU 2014-10 only impacted the consolidated financial statement presentation.
	3.              In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). This update requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, ASU 2013-02 requires presentation, either on the face of the income statement or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by respective line items of net income, but only if the amounts reclassified are required to be reclassified in their entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about these amounts. The amendments in ASU 2013-02 will be effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. The Company adopted ASU 2013-02 in the first quarter of fiscal year 2014. The adoption of ASU 2013-02 did not have any material effect on the consolidated financial statement presentation.

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Aug. 31, 2014
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Schedule of Annual Depreciation Rates	'
	Annual rates of depreciation are as follows:
		%
	Computers and peripheral equipment	33
	Office furniture and equipment	15-33

SHORT_TERM_DEPOSITS_Tables

SHORT TERM DEPOSITS (Tables)	12 Months Ended
	Aug. 31, 2014
SHORT TERM DEPOSITS [Abstract]	'
Schedule of Short Term Deposits	'
			31-Aug
			2014			2013
		Annual		Amount		Annual			Amount
		interest				interest
		rate				rate
	Dollar deposits		0.12-0.6%	$	18,481		0.6-1.06	%	$	5,112
	NIS deposits				-		1.93%			135
				$	18,481				$	5,247

PROPERTY_AND_EQUIPMENT_NET_Tab

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Aug. 31, 2014
PROPERTY AND EQUIPMENT, NET [Abstract]	'
Schedule of Property and Equipment	'
		31-Aug
		2014		2013
	Cost:
	Leasehold improvements	$	78	$	76
	Office furniture and equipment		28		20
	Computers and peripheral equipment		38		34
			144		130
	Less - accumulated depreciation and amortization		130		124
		$	14	$	6

WARRANTS_Tables

WARRANTS (Tables)	12 Months Ended
	Aug. 31, 2014
WARRANTS [Abstract]	'
Schedule of Liabilities Measured at Fair Value Using Significant Unobservable Inputs	'
		Year ended August 31,
		2013			2012
	Carrying value at the beginning of the period	$	637		$	-
	Additions		28			494
	Changes in fair value		(44	)		143
	Exchange of warrants		(621	)		-
	Carrying value at the end of the period	$	-		$	637
	See note 8g with respect to outstanding warrants.

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Aug. 31, 2014
STOCK HOLDERS' EQUITY [Abstract]	'
Schedule of Warrant Activity	'
	The following table presents the warrant activity for the years ended August 31, 2014, 2013 and 2012:
		2014					2013					2012
		Warrants			Weighted-Average Exercise Price		Warrants			Weighted-Average Exercise Price*				Weighted-Average Exercise Price*
												Warrants
	Warrants outstanding as of September 1		1,215,034		$	5.33		883,191		$	5.56		352,883	$	6
	Issued		-			-		353,285		$	4.79		530,308	$	5.28
	Exercised		(261,665	)	$	6		(21,442	)	$	6		-		-
	Warrants outstanding as of August 31		953,369		$	5.15		1,215,034		$	5.33		883,191	$	5.56
	Warrants exercisable as of August 31		952,258		$	5		1,213,478		$	5.33		852,024	$	5.55
	* See note 5 with regards to the amendment of price of certain warrants during the years ended August 31, 2012 and 2013.

STOCKBASED_COMPENSATION_Tables

STOCKBASED COMPENSATION (Tables)	12 Months Ended
	Aug. 31, 2014
STOCK BASED COMPENSATION [Abstract]	'
Schedule of Fair Value Assumptions	'
		For options granted in
		the year ended August
		31
		2014			2013			2012
	Expected option life (years)	5.21-5.25			5.75-6			5.5-5.75
	Expected stock price volatility (%)	82.06			64.35-75.46			76.03
	Risk free interest rate (%)	1.65			0.92-1.01			0.83-1.0375
	Expected dividend yield (%)	0.0			0			0
Schedule of Stock Option Activity for Employees	'
		Year ended August 31,
		2014						2013						2012
		Number			Weighted			Number			Weighted			Number			Weighted
		of			average			of			average			of			average
		options			exercise			options			exercise			options			exercise
					price						price						price
					$						$						$
	Options outstanding at beginning of year		1,049,249			4.13			932,116			3.72			834,116			3.84
	Changes during the year:
	Granted - at market price		149,200			12.45			100,800			7.88			244,334			4.08
	Granted - above market price		-			-			24,667			6			-			-
	Expired		-			-			-			-			(141,667	)		5.4
	Forfeited		-			-			-			-			(4,667	)		5.64
	Exercised		(289,548	)		0.18			(8,334	)		5.04			-			-
	Options outstanding at end of year		908,901			6.75			1,049,249			4.13			932,116			3.72
	Options exercisable at end of year		786,328						870,883						717,088
	Weighted average fair value of options granted during the year	$	8.31					$	4.55					$	2.65
Summary of Information for Options Granted and Exercisable for Employees	'
	The following table presents summary information concerning the options granted to employees and directors outstanding as of August 31, 2014:
	Range of	Number			Weighted			Weighted			Aggregate
	exercise	outstanding			Average			average			intrinsic value
	prices				Remaining			exercise
					Contractual			price
					Life
	$				Years				$
	4.08 to 6.00		514,901			6.7			4.95			2,672
	6.48 to 7.88		244,800			5.72			7.06			755
	12.45		149,200			9.61			12.45			-
			908,901			6.91			6.75			3,427
	The following table presents summary information concerning the options granted to employees and directors exercisable as of August 31, 2014:
	Range of	Number			Weighted			Weighted			Aggregate
	exercise	exercisable			Average			average			intrinsic value
	prices				Remaining			exercise
					Contractual			price
					Life
	$				Years				$
	4.08 to 6.00		505,818			6.67			4.97			2,617
	6.48 to 7.88		190,200			4.88			6.82			631
	12.45		90,310			9.61			12.45			-
			786,328			6.58			6.27			3,248
Schedule of Stock Option Activity for Non-Employees	'
		Year ended August 31
		2014						2013						2012
		Number			Weighted			Number			Weighted			Number			Weighted
		of			average			of			average			of			average
		options			exercise			options			exercise			options			exercise
					price						price						price
					$						$						$
	Options outstanding at beginning of year		79,689			7.21			79,689			7.21			79,689			7.21
	Changes during the year:
	Exercised		(17,468	)		7.49			-						-			-
	Options outstanding at end of year		62,221			7.13			79,689			7.21			79,689			7.21
	Options exercisable at end of year		53,888						47,469						54,683
Summary of Information for Options Granted and Exercisable for Non-Employees	'
	The following table presents summary information concerning the options granted to non-employees outstanding as of August 31, 2014:
	Range of		Number			Weighted			Weighted			Aggregate
	exercise		outstanding			Average			Average			intrinsic value
	prices					Remaining			Exercise
						Contractual			Price
						Life
	$					Years				$
	4.08 to 6.00			37,219			3.94			5.79			162
	9.12			25,002			2.99			9.12			25
				62,221			3.56			7.13			187
	The following table presents summary information concerning the options granted to non-employee exercisable as of August 31, 2014:
	Range of	Number			Weighted			Weighted			Aggregate
	exercise	exercisable			Average			average			intrinsic value
	prices				Remaining			exercise
					Contractual			price
					Life
	$				Years			$
	4.08 to 6.00		28,886			3.21			5.73			128
	9.12		25,002			2.99			9.12			25
			53,888			3.11			7.3			153

FINANCIAL_INCOME_AND_EXPENSES_

FINANCIAL INCOME AND EXPENSES (Tables)	12 Months Ended
	Aug. 31, 2014
FINANCIAL INCOME AND EXPENSES [Abstract]	'
Schedule of Financial Income	'
		Year ended August 31
			2014		2013		2012
	Gain on sale of marketable securities (note 3)		$	80	$	90	$	-
	Changes in fair value of warrants			-		44		-
	Income from interest on deposits			138		19		13
	Exchange rate differences			7		-		-
	Other			-		27		-
			$	225	$	180	$	13
Schedule of Financial Expenses	'
			Year ended August 31
			2014		2013		2012
	Exchange of warrants		$	-	$	297	$	-
	Changes in fair value of warrants			-		-		143
	Exchange rate differences			-		3		35
	Bank commissions			11		13		15
	Other			-		-		6
			$	11	$	313	$	199

TAXES_ON_INCOME_Tables

TAXES ON INCOME (Tables)	12 Months Ended
	Aug. 31, 2014
TAXES ON INCOME [Abstract]	'
Schedule of Deferred Income Taxes	'
			31-Aug
			2014			2013			2012
	In respect of:
	Net operating loss carryforward			4,890			3,993			3,190
	Research and development expenses			688			339			18
	Less - valuation allowance			(5,578	)		(4,332	)		(3,208	)
	Net deferred tax assets			-			-			-
Schedule of Income Taxes Included in the Income Statements	'
				Year ended
				31-Aug
				2014			2013			2012
	Loss before taxes on income:
	U.S.				893			1,186			599
	Outside U.S.				4,799			3,251			2,655
				$	5,692		$	4,437		$	3,254
	Income tax expenses (benefit):
	Current:
	U.S.				-			(13	)		(8	)
	Outside U.S.				4			(192	)		98
				$	4		$	(205	)	$	90
Schedule of Reconciliation of Income Taxes	'
				Year ended
				31-Aug
				2014				2013					2012
	Loss before income taxes as reported in the consolidated statement of comprehensive income (loss)			$	(5,692	)		$		(4,437	)		$	(3,254		)
	Statutory tax benefit				(1,992	)				(1,552	)				(1,139	)
	Increase (decrease) in income taxes resulting from:
	Change in the balance of the valuation allowance for deferred tax				1,104					902					517
	Disallowable deductions				480					374					120
	Increase in taxes resulting from different tax rates applicable to the Subsidiary				408					276					502
	Uncertain tax position				4					(205	)				90
	Taxes on income for the reported year			$	4			$		(205	)		$		90
Schedule of Unrecognized Tax Benefits Activity	'
				Year ended August 31
				2014					2013					2012
	Balance at Beginning of Year			$		23			$		228			$		138
	Increase (decrease) in uncertain tax positions for the current year					4					(205	)				90
	Balance at End of Year			$		27			$		23			$		228
Valuation Allowance Rollforward	'
		Year ended
		31-Aug
			Balance at beginning of period				Additions				Balance at end of period
	Allowance in respect of carryforward tax losses:
	Year ended August 31, 2014		$	4,332			$	1,246			$	5,578
	Year ended August 31, 2013		$	3,208			$	1,124			$	4,332
	Year ended August 31, 2012		$	1,813			$	1,395			$	3,208

RELATED_PARTIES_TRANSACTIONS_T

RELATED PARTIES - TRANSACTIONS (Tables)	12 Months Ended
	Aug. 31, 2014
RELATED PARTIES - TRANSACTIONS [Abstract]	'
Schedule of Balances with Related Parties	'
			31-Aug
			2014			2013
	Receivable		$	330		$	5
	Accounts payable and accrued expenses - KNRY		$	47		$	64
Schedule of Related Party Expenses	'
		31-Aug
		2014			2013			2012
	KNRY	$		671	$		448	$	318

SIGNIFICANT_ACCOUNTING_POLICIE3

SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	1 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 22, 2013	Aug. 31, 2014	Jul. 23, 2014	Aug. 31, 2013	Jan. 23, 2013	Aug. 31, 2014	Aug. 31, 2014	Aug. 31, 2014	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
	Rate					Computers and Peripheral Equipment [Member]	Office Furniture and Equipment [Member]	Office Furniture and Equipment [Member]	Stock Options and Warrants [Member]	Stock Options and Warrants [Member]	Stock Options and Warrants [Member]
							Minimum [Member]	Maximum [Member]
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Reverse stock split ratio	0.083333	'	'	'	'	'	'	'	'	'	'
Common stock, shares issued	86,500,000	10,102,555	'	7,937,872	7,200,000	'	'	'	'	'	'
Common stock, shares outstanding	86,500,000	10,102,555	'	7,937,872	7,200,000	'	'	'	'	'	'
Common stock, shares authorized	200,000,000	30,000,000	30,000,000	16,666,667	16,700,000	'	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Antidilutive securities	'	'	'	'	'	'	'	'	1,924,491	2,343,972	1,892,180
Fair value measurement	'	'	'	'	'	'	'	'	'	'	'
Restricted deposit	'	$16	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Depreciation rate	'	'	'	'	'	33.00%	15.00%	33.00%	'	'	'

SHORT_TERM_DEPOSITS_Details

SHORT TERM DEPOSITS (Details) (USD $)	Aug. 31, 2014	Aug. 31, 2013
In Thousands, unless otherwise specified
Short Term Investments [Line Items]	'	'
Amount	$18,481	$5,247
Dollars deposits [Member]	'	'
Short Term Investments [Line Items]	'	'
Amount	18,481	5,112
Dollars deposits [Member] | Minimum [Member]	'	'
Short Term Investments [Line Items]	'	'
Interest rate	0.12%	0.60%
Dollars deposits [Member] | Maximum [Member]	'	'
Short Term Investments [Line Items]	'	'
Interest rate	0.60%	1.06%
NIS deposits [Member]	'	'
Short Term Investments [Line Items]	'	'
Interest rate	'	1.93%
Amount	'	$135

MARKETABLE_SECURITIES_Details

MARKETABLE SECURITIES (Details) (USD $)	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2013	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
MARKETABLE SECURITIES [Abstract]	'	'	'	'
Number of shares sold	1,750,000	2,625,989	5,250,000	'
Proceeds from sale of securities	$56	$138	$170	'
Ownership percentage	'	9.80%	'	'
Amount reclassified to earnings	'	80	90	'
Cost of securities	'	$590	$652	'

PROPERTY_AND_EQUIPMENT_NET_Det

PROPERTY AND EQUIPMENT, NET (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
Property, Plant and Equipment [Line Items]	'	'	'
Cost	$144	$130	'
Less - accumulated depreciation and amortization	130	124	'
Property and equipment, net	14	6	'
Depreciation expenses	6	5	15
Leasehold Improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Cost	78	76	'
Office Furniture and Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Cost	28	20	'
Computers and Peripheral Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Cost	$38	$34	'

WARRANTS_Details

WARRANTS (Details) (USD $)	12 Months Ended				3 Months Ended	24 Months Ended		1 Months Ended
In Thousands, except Share data, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2012	Nov. 30, 2012	Aug. 31, 2012	Nov. 29, 2012	Nov. 29, 2012	Nov. 30, 2012
				2011 Warrants [Member]	Three Warrants [Member]	Three Warrants [Member]	Three Warrants [Member]	New Warrant [Member]	CEO Options [Member]
Warrants [Line Items]	'	'	'	'	'	'	'	'	'
Number of warrants granted	'	'	'	'	137,311	311,797	'	137,311	'
Warrant term	'	'	'	'	'	'5 years	'	'4 years	'
Number of shares authorized by warrant	'	'	'	290,459	'	'	'	'	112,690
Exercise price per share	'	'	'	$3.77	'	$6	$3.77	$7.20	'
Warrants (notes 6)	'	'	'	'	'	'	'	$145	$168
Expected dividend yield (%)	0.00%	0.00%	0.00%	'	'	'	'	0.00%	'
Expected option life (years)	'	'	'	'	'	'	'	'4 years	'
Expected volatility	82.06%	'	76.03%	'	'	'	'	62.29%	'
Risk-free interest rate	1.65%	'	'	'	'	'	'	0.57%	'
Financial expense	'	'	'	'	297	'	'	'	'
Carrying value at the beginning of the period	'	637	'	'	'	'	'	'	'
Additions	'	28	494	'	'	'	'	'	'
Changes in fair value	'	-44	143	'	'	'	'	'	'
Exchange of warrants	'	-621	'	'	'	'	'	'	'
Carrying value at the end of the period	'	'	$637	'	'	'	'	'	'

EMPLOYEES_RIGHTS_UPON_RETIREME1

EMPLOYEES RIGHTS UPON RETIREMENT (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]	'	'	'
Severance pay insurance deposits	$2	$2	$4
Severance pay expenses	26	23	6
Severance pay expenses in respect of Contribution Plan	26	13	7
Severance pay expected deposit	$27	'	'

COMMITMENTS_Service_Agreements

COMMITMENTS (Service Agreements) (Details) (USD $)

12 Months Ended

1 Months Ended

149 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

7 Months Ended

12 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

In Thousands, except Share data, unless otherwise specified

Aug. 31, 2014

Aug. 31, 2013

Aug. 31, 2012

Mar. 31, 2011

Aug. 31, 2014

Aug. 31, 2014

Aug. 31, 2011

13-May-14

Nov. 04, 2013

Jul. 11, 2013

Apr. 15, 2013

15-May-12

Mar. 14, 2012

Dec. 12, 2011

Aug. 31, 2014

Aug. 31, 2013

Jul. 21, 2014

Aug. 31, 2014

Aug. 31, 2014

Aug. 31, 2014

Aug. 31, 2013

Aug. 31, 2014

Aug. 31, 2014

Aug. 31, 2014

Aug. 31, 2014

Aug. 31, 2014

Entera [Member]

Hadasit [Member]

Consultant [Member]

Consultant [Member]

Advisor [Member]

Advisor [Member]

Advisor [Member]

Advisor [Member]

Advisor [Member]

Advisor [Member]

Advisor [Member]

Advisor [Member]

First Master Service Agreement [Member]

Clinical Research Organization Service Agreement [Member]

Clinical Research Organization Service Agreement [Member]

Clinical Research Organization Service Agreement [Member]

Clinical Research Organization Service Agreement [Member]

Clinical Research Organization Service Agreement [Member]

Second Master Service Agreement [Member]

Third Master Service Agreement [Member]

Fourth Master Service Agreement [Member]

Fourth Master Service Agreement [Member]

Fourth Master Service Agreement [Member]

D.N.A. [Member]

Long-term Purchase Commitment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments for consulting services

'

'

'

'

$200

'

'

'

'

'

'

'

'

'

'

$102

$3,290

'

'

$280

$333

$311

$217

'

'

$214

Commitments for bonus payments upon achieving certain milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600

'

'

'

'

Consulting services

'

'

'

'

95

'

'

'

'

'

'

'

'

'

'

'

'

64

182

'

'

40

'

47

103

'

Agreement term

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments for consulting service, monthly fixed fee

'

'

'

'

'

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ownership percentage retained

'

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual interest rate (as a percent)

'

'

'

0.45%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment in Entera

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount of promissory note received

'

'

'

450

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ordinary shares received

'

'

'

8,404,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty percentage

'

'

'

3.00%

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options granted

'

'

'

'

'

'

20,834

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options granted, exercise price

'

'

'

'

'

'

$6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capitalized cost

'

'

'

'

'

111

62

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend yield

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected volatility

'

'

'

'

'

81.31%

78.65%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate

'

'

'

'

'

2.05%

3.62%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected term

'

'

'

'

'

'6 years 5 months 16 days

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares authorized for issuance for services

'

'

'

'

'

'

'

15,000

'

'

15,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued for services

'

'

'

'

'

'

'

'

10,000

5,000

'

'

'

6,917

3,750

'

'

'

'

'

'

'

'

'

'

'

Shares issued for services rendered

$102

$244

$108

'

'

'

'

'

$64

$35

'

$25

$27

$25

$38

'

'

'

'

'

'

'

'

'

'

'

COMMITMENTS_Leases_Details

COMMITMENTS (Leases) (Details)	12 Months Ended				12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2014	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
	Office Building [Member]	Office Building [Member]	Office Building [Member]	Office Building [Member]	Vehicles [Member]	Vehicles [Member]	Vehicles [Member]
	USD ($)	USD ($)	USD ($)	ILS	USD ($)	USD ($)	USD ($)
Operating Leased Assets [Line Items]	'	'	'	'	'	'	'
Operating lease term	'36 months	'	'57 months	'	'3 years	'	'
Annual lease payments:	'	'	'	'	'	'	'
2015	$25	'	'	89	$18	'	'
2016	25	'	'	89	14	'	'
2017	2	'	'	89	'	'	'
Lease expense	27	13	9	'	28	30	30
Deposit for lease	'	'	'	'	$2	'	'

COMMITMENTS_Research_Grants_De

COMMITMENTS (Research Grants) (Details) (USD $)	12 Months Ended			149 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2014
Bio-Jerusalem [Member]	'	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'
Royalty percentage	4.00%	'	'	4.00%
Royalty percentage, maximum percentage of grants received	100.00%	'	'	100.00%
Royalty liability	$0	'	'	$0
Grants receivable	65	'	'	65
Grants received	0	12	'	'
Chief Scientist Office [Member]	'	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'
Royalty percentage, maximum percentage of grants received	100.00%	'	'	100.00%
Grants received	$428	$297	$373	$2,066
Chief Scientist Office [Member] | Minimum [Member]	'	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'
Royalty percentage	3.00%	'	'	3.00%
Chief Scientist Office [Member] | Maximum [Member]	'	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'
Royalty percentage	3.50%	'	'	3.50%

STOCK_HOLDERS_EQUITY_Narrative

STOCK HOLDERS' EQUITY (Narrative) (Details) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

In Thousands, except Share data, unless otherwise specified

Nov. 30, 2014

Aug. 31, 2014

Aug. 31, 2013

Aug. 31, 2012

Jul. 23, 2014

Jan. 23, 2013

Jan. 22, 2013

Aug. 31, 2014

Aug. 31, 2014

Aug. 31, 2012

Nov. 30, 2012

Jul. 30, 2013

Aug. 31, 2012

Dec. 24, 2013

Aug. 31, 2012

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2012

Oct. 31, 2012

Minimum [Member]

Maximum [Member]

Securities Purchase Agreement [Member]

Securities Purchase Agreement [Member]

Securities Purchase Agreement Two [Member]

Securities Purchase Agreement Two [Member]

Securities Purchase Agreement Three [Member]

Leading Investor [Member]

Leading Investor [Member]

Other Individual [Member]

Director [Member]

D.N.A. [Member]

item

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Securities Purchase Agreements, number of units

'

'

'

'

'

'

'

'

'

801,942

329,872

658,144

5,652

1,580,000

225,226

33,784

'

'

'

Number of shares to be sold

'

'

'

'

'

'

'

'

'

'

'

'

5,652

'

'

'

1,127

12,745

199,172

Number of shares authorized by warrant

'

'

'

'

'

'

'

'

'

'

'

'

2,826

'

'

'

564

6,373

'

Securities Purchase Agreements, purchase price per unit

'

'

'

'

'

'

'

'

'

$4.44

$4.44

$7

'

$10

'

'

'

'

'

Proceeds from issuance of shares

'

$14,887

[1]

$5,715

[1]

$3,489

[1]

'

'

'

'

'

$3,560

$1,464

$4,239

$25

'

'

'

'

'

$629

Securities Purchase Agreements, number of shares per unit

'

'

'

'

'

'

'

'

'

1

1

'

1

'

'

'

'

'

'

Securities Purchase Agreements Number Of Warrants Per Unit

'

'

'

'

'

'

'

'

'

1

1

'

1

'

'

'

'

'

'

Securities Purchase Agreements, number of shares per warrant

'

'

'

'

'

'

'

'

'

0.5

0.5

'

0.5

'

'

'

'

'

'

Warrant term

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'

'5 years

'

'

'

'

'

'

Value of shares issued for services

'

102

244

108

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finders fee

150

'

'

'

'

'

'

'

'

'

'

255

71

'

'

'

13

'

'

Option to purchase shares of D.N.A.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,637,611

Percent shares owned by investor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

5.00%

'

'

'

Number of institutional investors

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

Proceeds from issuance of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

14,887

'

'

'

'

'

Stock issuance costs including commisions

'

'

'

'

'

'

'

'

'

'

'

'

'

$816

'

'

'

'

'

Common stock, shares authorized

'

30,000,000

16,666,667

'

30,000,000

16,700,000

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding warrants

'

953,369

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of outstanding warrants (in dollars per share)

'

'

'

'

'

'

'

$3.77

$7.20

$6

$6

'

'

'

'

'

'

'

'

[1]

See notes 8a, 8b and 8d.

STOCKHOLDERS_EQUITY_Schedule_o

STOCKHOLDERS' EQUITY (Schedule of Warrant Activity) (Details) (Warrants [Member], USD $)	12 Months Ended
	Aug. 31, 2014		Aug. 31, 2013		Aug. 31, 2012
Warrants [Member]	'		'		'
Warrants	'		'		'
Warrants outstanding as of September 1	1,215,034		883,191		352,883
Issued	'		353,285		530,308
Exercised	-261,665		-21,442		'
Warrants outstanding as of August 31	953,369		1,215,034		883,191
Warrants exercisable as of August 31	952,258		1,213,478		852,024
Weighted-Average Exercise Price	'		'		'
Warrants outstanding as of September 1	$5.33	[1]	$5.56	[1]	$6	[1]
Issued	'		$4.79	[1]	$5.28	[1]
Exercised	$6		$6	[1]	'	[1]
Warrants outstanding as of August 31	$5.15		$5.33	[1]	$5.56	[1]
Warrants exercisable as of August 31	$5		$5.33	[1]	$5.55	[1]
[1]	* See note 5 with regards to the amendment of price of certain warrants during the years ended August 31, 2012 and 2013.

STOCK_BASED_COMPENSATION_Narra

STOCK BASED COMPENSATION (Narrative) (Details) (USD $)	0 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Aug. 08, 2012	Apr. 30, 2014	Aug. 08, 2012	Apr. 30, 2014	Aug. 31, 2013	Aug. 08, 2012	Aug. 31, 2014
	Nadav Kidron and Miriam Kidron [Member]	Nadav Kidron and Miriam Kidron [Member]	Directors [Member]	Directors [Member]	Directors [Member]	Miriam Kidron [Member]	Amended and Restated 2008 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Number of shares reserved for grant	'	'	'	'	'	'	1,400,000
Options granted	144,000	94,268	43,334	52,376	20,000	'	'
Options granted, exercise price	$4.08	$12.45	$4.08	$12.45	$6	'	'
Options vested in period	42,000	31,420	'	'	'	'	'
Number of vesting installments	'	8	2	2	2	'	'
Fair value of options granted	$374	$781	$115	$0	$41	'	'
Number of options to vest each installment	6,000	7,586	'	'	'	'	'
Expiration date	7-Aug-22	9-Apr-24	7-Aug-22	9-Apr-24	'	'	'
Expected dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	'	'
Expected volatility	76.03%	82.06%	76.03%	82.06%	64.35%	'	'
Risk-free interest rate	0.83%	1.65%	1.04%	1.65%	1.01%	'	'
Expected term	'5 years 6 months	'5 years 2 months 16 days	'5 years 9 months	'5 years 3 months	'5 years 9 months	'	'
Number of shares authorized by warrant	'	'	'	'	'	280,114	'

STOCKBASED_COMPENSATION_Schedu

STOCKBASED COMPENSATION (Schedule of Fair Value Assumptions) (Details)	12 Months Ended
	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected stock price volatility (%)	82.06%	'	76.03%
Expected stock price volatility (%), minimum	'	64.35%	'
Expected stock price volatility (%), maximum	'	75.46%	'
Risk-free interest rate (%)	1.65%	'	'
Risk-free interest rate (%), minimum	'	0.92%	0.83%
Risk-free interest rate (%), maximum	'	1.01%	1.04%
Expected dividend yield (%)	0.00%	0.00%	0.00%
Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected option life (years)	'5 years 2 months 16 days	'5 years 9 months	'5 years 6 months
Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected option life (years)	'5 years 3 months	'6 years	'5 years 9 months

STOCKBASED_COMPENSATION_Schedu1

STOCKBASED COMPENSATION (Schedule of Stock Option Activity) (Details) (USD $)	12 Months Ended
	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012	Sep. 30, 2014
Employees [Member]	'	'	'	'
Number of options	'	'	'	'
Options outstanding at beginning of year	1,049,249	932,116	834,116	'
Granted - at market price	149,200	100,800	244,334	'
Granted - above market price	'	24,667	'	'
Expired	'	'	-141,667	'
Forfeited	'	'	-4,667	'
Exercised	-289,548	-8,334	'	'
Options outstanding at end of year	908,901	1,049,249	932,116	'
Options exercisable at end of year	786,328	870,883	717,088	'
Weighted average grant-date fair value	$8.31	$4.55	$2.65	'
Weighted average exercise price	'	'	'	'
Options outstanding at beginning of year	$4.13	$3.72	$3.84	$6.75
Granted - at market price	$12.45	$7.88	$4.08	'
Granted - above market price	'	$6	'	'
Expired	'	'	'	'
Forfeited	'	'	$5.64	'
Exercised	$0.18	$5.04	'	'
Options outstanding at end of year	'	$4.13	$3.72	$6.75
Stockbased compensation expense	$1,422,000	$563,000	$201,000	'
Intrinsic value of options exercised	2,847,000	18,000	'	'
Unrecognized compensation expense	292	'	'	'
Period over which compensation expense will be recognized	'20 months	'	'	'
Nonemployees [Member]	'	'	'	'
Number of options	'	'	'	'
Options outstanding at beginning of year	79,689	79,689	79,689	'
Exercised	-17,468	'	'	'
Options outstanding at end of year	62,221	79,689	79,689	'
Options exercisable at end of year	53,888	47,469	54,683	'
Weighted average exercise price	'	'	'	'
Options outstanding at beginning of year	$7.21	$7.21	$7.21	'
Exercised	$7.49	'	'	'
Options outstanding at end of year	$7.13	$7.21	$7.21	'
Stockbased compensation expense	46,000	156,000	117,000	'
Intrinsic value of options exercised	187,000	'	'	'
Unrecognized compensation expense	$49,000	'	'	'
Period over which compensation expense will be recognized	'18 months	'	'	'

STOCKBASED_COMPENSATION_Summar

STOCKBASED COMPENSATION (Summary of Information for Options Outstanding and Exercisable by Exercise Price Range) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Aug. 31, 2014
Employees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	908,901
Outstanding, weighted average remaining contractual life, years	'6 years 10 months 28 days
Outstanding, weighted average exercise price	$6.75
Outstanding, aggregate intrinsic value	$3,427
Number exercisable	786,328
Exercisable, weighted average remaining contractual life, years	'6 years 6 months 29 days
Exercisable, weighted average exercise price	$6.27
Exercisable, aggregate intrinsic value	3,248
Nonemployees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	62,221
Outstanding, weighted average remaining contractual life, years	'3 years 6 months 22 days
Outstanding, weighted average exercise price	$7.13
Outstanding, aggregate intrinsic value	187
Number exercisable	53,888
Exercisable, weighted average remaining contractual life, years	'3 years 1 month 10 days
Exercisable, weighted average exercise price	$7.30
Exercisable, aggregate intrinsic value	153
$4.08 to 6.00 [Member] | Employees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	514,901
Outstanding, weighted average remaining contractual life, years	'6 years 8 months 12 days
Outstanding, weighted average exercise price	$4.95
Outstanding, aggregate intrinsic value	2,672
Number exercisable	505,818
Exercisable, weighted average remaining contractual life, years	'6 years 8 months 1 day
Exercisable, weighted average exercise price	$4.97
Exercisable, aggregate intrinsic value	2,617
$4.08 to 6.00 [Member] | Nonemployees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	37,219
Outstanding, weighted average remaining contractual life, years	'3 years 11 months 9 days
Outstanding, weighted average exercise price	$5.79
Outstanding, aggregate intrinsic value	162
Number exercisable	28,886
Exercisable, weighted average remaining contractual life, years	'3 years 2 months 16 days
Exercisable, weighted average exercise price	$5.73
Exercisable, aggregate intrinsic value	128
$6.48 to 7.88 [Member] | Employees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	244,800
Outstanding, weighted average remaining contractual life, years	'5 years 8 months 19 days
Outstanding, weighted average exercise price	$7.06
Outstanding, aggregate intrinsic value	755
Number exercisable	190,200
Exercisable, weighted average remaining contractual life, years	'4 years 10 months 17 days
Exercisable, weighted average exercise price	$6.82
Exercisable, aggregate intrinsic value	631
$12.45 [Member] | Employees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	149,200
Outstanding, weighted average remaining contractual life, years	'9 years 7 months 10 days
Outstanding, weighted average exercise price	$12.45
Outstanding, aggregate intrinsic value	'
Number exercisable	90,310
Exercisable, weighted average remaining contractual life, years	'9 years 7 months 10 days
Exercisable, weighted average exercise price	$12.45
Exercisable, aggregate intrinsic value	'
$9.12 [Member] | Nonemployees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	25,002
Outstanding, weighted average remaining contractual life, years	'2 years 11 months 27 days
Outstanding, weighted average exercise price	$9.12
Outstanding, aggregate intrinsic value	25
Number exercisable	25,002
Exercisable, weighted average remaining contractual life, years	'2 years 11 months 27 days
Exercisable, weighted average exercise price	$9.12
Exercisable, aggregate intrinsic value	$25

FINANCIAL_INCOME_AND_EXPENSES_1

FINANCIAL INCOME AND EXPENSES (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
Financial income	'	'	'
Gain on sale of marketable securities (note 3)	$80	$90	'
Changes in fair value of warrants	'	44	'
Income from interest on deposits	138	19	13
Exchange rate differences	7	'	'
Other	'	27	'
Financial income	225	180	13
Financial expenses	'	'	'
Exchange of warrants	'	297	'
Changes in fair value of warrants	'	'	143
Exchange rate differences	'	3	35
Bank commissions	11	13	15
Other	'	'	6
Financial expenses	$11	$313	$199

TAXES_ON_INCOME_Narrative_Deta

TAXES ON INCOME (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013
Taxes On Income [Line Items]	'	'
Corporate tax rate	35.00%	'
Net operating loss carryforwards	$6,626	$5,605
Penalties related to tax contingencies	0	0
Subsidiaries [Member]	'	'
Taxes On Income [Line Items]	'	'
Corporate tax rate	26.50%	25.00%
Net operating loss carryforwards	$9,713	$7,664

TAXES_ON_INCOME_Schedule_of_De

TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details) (USD $)	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2011
In Thousands, unless otherwise specified
TAXES ON INCOME [Abstract]	'	'	'	'
Net operating loss carryforward	$4,890	$3,993	$3,190	'
Research and development expenses	688	339	18	'
Less - Valuation allowance	-5,578	-4,332	-3,208	-1,813
Net deferred tax assets	'	'	'	'

TAXES_ON_INCOME_Schedule_of_In

TAXES ON INCOME (Schedule of Income Taxes Included in the Income Statements) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
TAXES ON INCOME [Abstract]	'	'	'
U.S.	$893	$1,186	$599
Outside U.S.	4,799	3,251	2,655
Loss before taxes on income	5,692	4,437	3,254
U.S.	'	-13	-8
Outside U.S.	4	-192	98
Taxes on income	$4	($205)	$90

TAXES_ON_INCOME_Schedule_of_Re

TAXES ON INCOME (Schedule of Reconciliation of Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
TAXES ON INCOME [Abstract]	'	'	'
Loss before income taxes as reported in the consolidated statement of comprehensive income (loss)	($5,692)	($4,437)	($3,254)
Statutory tax benefit	-1,992	-1,552	-1,139
Change in the balance of the valuation allowance for deferred tax	1,104	902	517
Disallowable deductions	480	374	120
Increase in taxes resulting from different tax rates applicable to non U.S. subsidiary	408	276	502
Uncertain tax position	4	-205	90
Taxes on income	$4	($205)	$90

TAXES_ON_INCOME_Schedule_of_Un

TAXES ON INCOME (Schedule of Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
TAXES ON INCOME [Abstract]	'	'	'
Balance at Beginning of Year	$23	$228	$138
Increase (decrease) in uncertain tax positions for the current year	4	-205	90
Balance at End of Year	$27	$23	$228

TAXES_ON_INCOME_Valuation_Allo

TAXES ON INCOME (Valuation Allowance Rollforward) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
TAXES ON INCOME [Abstract]	'	'	'
Balance at beginning of period	$4,332	$3,208	$1,813
Additions	1,246	1,124	1,395
Balance at end of period	$5,578	$4,332	$3,208

RELATED_PARTIES_TRANSACTIONS_N

RELATED PARTIES - TRANSACTIONS (Narrative) (Details)	12 Months Ended				0 Months Ended
	Aug. 31, 2014	Aug. 31, 2013	Jul. 01, 2008	Jul. 01, 2008	Mar. 18, 2014	Feb. 24, 2014	Jul. 17, 2013	Feb. 24, 2014	Jul. 17, 2013
	Director [Member]	Director [Member]	KNRY [Member]	KNRY [Member]	CEO [Member]	CEO [Member]	CEO [Member]	CTO [Member]	CTO [Member]
	USD ($)	USD ($)	USD ($)	ILS	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'
Amount of transaction	$40,000	$39,000	'	'	'	'	'	'	'
Monthly payment under Consulting Agreements	'	'	14,000	50,400	'	'	'	'	'
Annual payment under Consulting Agreements	'	'	'	'	'	'	250,000	'	200,000
Exchange rate (in NIS per U.S. dollar)	'	'	'	'	'	'	3.6	'	3.6
Actual payment	'	'	'	'	'	'	257,000	'	206,000
Car and cash bonus	'	'	'	'	'	'	60,000	'	20,000
Cash bonus	'	'	'	'	'	120,000	'	65,000	'
Temporary increase in compensation per month for a specific period	'	'	'	'	$7,000	'	'	'	'

RELATED_PARTIES_TRANSACTIONS_S

RELATED PARTIES - TRANSACTIONS (Schedule of Balances with Related Parties) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2012
Related Party Transaction [Line Items]	'	'	'
Receivable	$330	$5	'
Accounts payable and accrued expenses	47	64	'
KNRY [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Receivable	330	5	'
Accounts payable and accrued expenses	47	64	'
Expenses to related parties	$671	$448	$318

SUBSEQUENT_EVENT_Details

SUBSEQUENT EVENT (Details) (USD $)	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Nov. 30, 2014
Subsequent Event [Line Items]	'
Finders fee	$150
Securities Purchase Agreement Four [Member]	'
Subsequent Event [Line Items]	'
Securities Purchase Agreements, number of units	696,378
Securities Purchase Agreements, purchase price per unit	$7.18